Press "Enter" to skip to content

Indian pharma sector expected to grow at 10-12 pc during FY19-22, outlook stable: Icra

It, however, said increased cost related to regulatory compliances, especially for the US market, price controls across markets and mandatory genericisation for Indian market remained key risks.

Original source:

Also Read:   Covid-19 outbreak: Pharma companies airlift inputs to deal with supply disruptions